rs587780577
Variant summary
Our verdict is Pathogenic. Variant got 15 ACMG points: 15P and 0B. PM2_SupportingPS4_ModeratePM6PVS1PP4PP1
This summary comes from the ClinGen Evidence Repository: The p.M1? variant in UBE3A is predicted to cause a truncated or absent protein by altering the start codon of the coding sequence in a UBE3A where loss-of-function is an established disease mechanism. Pathogenic variants affecting the start site have been described in affected patients (PVS1). The p.M1? variant has been observed in 3 other individuals with Angelman syndrome (PMID 29737008, 25212744) (PS4_Moderate). The p.M1? variant in UBE3A is absent from gnomAD (PM2_Supporting). The p.M1? variant in UBE3A has been reported as a de novo occurrence (biological parentage unconfirmed) in an individual with Angelman syndrome (PMID 29737008) (PM6). The variant has been reported to segregate in two informative meioses (PP1). The p.M1? variant in UBE3A has been reported in an individual with a clinical phenotype suggestive of Angelman syndrome (PMID 29737008, 25212744) (PP4). In summary, the p.M1? variant in UBE3A is classified as pathogenic for Angelman syndrome based on the ACMG/AMP criteria (PVS1, PS4_moderate, PM2_supporting, PM6, PP1, PP4). LINK:https://erepo.genome.network/evrepo/ui/classification/CA333472/MONDO:0007113/016
Frequency
Consequence
NM_130839.5 missense, splice_region
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 15 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
UBE3A | NM_130839.5 | c.62T>C | p.Met21Thr | missense_variant, splice_region_variant | 4/13 | ENST00000648336.2 | NP_570854.1 | |
SNHG14 | NR_146177.1 | n.18589-13327A>G | intron_variant, non_coding_transcript_variant |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
UBE3A | ENST00000648336.2 | c.62T>C | p.Met21Thr | missense_variant, splice_region_variant | 4/13 | NM_130839.5 | ENSP00000497572 | P1 | ||
SNHG14 | ENST00000656420.1 | n.5457-13327A>G | intron_variant, non_coding_transcript_variant |
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome Cov.: 31
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Angelman syndrome Pathogenic:2
Pathogenic, no assertion criteria provided | clinical testing | Baylor Genetics | Feb 14, 2014 | - - |
Pathogenic, reviewed by expert panel | curation | ClinGen Rett and Angelman-like Disorders Variant Curation Expert Panel | Mar 26, 2021 | The p.M1? variant in UBE3A is predicted to cause a truncated or absent protein by altering the start codon of the coding sequence in a UBE3A where loss-of-function is an established disease mechanism. Pathogenic variants affecting the start site have been described in affected patients (PVS1). The p.M1? variant has been observed in 3 other individuals with Angelman syndrome (PMID 29737008, 25212744) (PS4_Moderate). The p.M1? variant in UBE3A is absent from gnomAD (PM2_Supporting). The p.M1? variant in UBE3A has been reported as a de novo occurrence (biological parentage unconfirmed) in an individual with Angelman syndrome (PMID 29737008) (PM6). The variant has been reported to segregate in two informative meioses (PP1). The p.M1? variant in UBE3A has been reported in an individual with a clinical phenotype suggestive of Angelman syndrome (PMID 29737008, 25212744) (PP4). In summary, the p.M1? variant in UBE3A is classified as pathogenic for Angelman syndrome based on the ACMG/AMP criteria (PVS1, PS4_moderate, PM2_supporting, PM6, PP1, PP4). - |
not provided Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Eurofins Ntd Llc (ga) | Jan 28, 2015 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at